Seven Bedri, Yoruk Ozgur, Varoglu Erhan, Ucuncu Harun, Sahin Ali, Kursad Ayan Arif, Sutbeyaz Yavuz
Department of Nuclear Medicine, Ataturk University, Medical School, 25240 Erzurum, Turkey.
Hell J Nucl Med. 2009 May-Aug;12(2):119-22.
The purpose of this study was to assess the effect of levocetirizine (xyzal) on salivary glands function in patients with allergic rhinitis using technetium-99m pertechnetate ((99m)Tc-P) salivary gland scintigraphy. The study population consisted of 67 patients with allergic rhinitis and 31 healthy controls (14 males and 17 females, mean age 30.1+/-6.8 years). The patients were divided into two groups: an untreated patient Group of 32 patients, 17 males and 15 females, mean age 29.9+/-6.5 years and a levocetirizine-treated with 5mg.day(-1) for 4 weeks patient Group, consisted of 35 patients, 16 males and 19 females, mean age 33.5+/-7.8 years. All patients and healthy controls underwent salivary glands scintigraphy. After the intravenous administration of 185 MBq of (99m)Tc-P, dynamic salivary glands scintigraphy was performed for 25 min. By the time-activity curves, the following glandular function parameters were calculated for the parotid and submandibular salivary glands: uptake ratio, maximum accumulation, and ejection fraction. Our results showed: All functional parameters obtained for the untreated patient Group were significantly lower than for the levocetirizine-treated patient Group and healthy controls (P<0.05). There was no significant difference in any functional parameters between the levocetirizine-treated patient Group and healthy controls (P>0.05). In conclusion, results of our study indicate that patients with allergic rhinitis treated with levocetirizine showed a significantly higher salivary glands function compared with untreated patients and healthy controls. Levocetirizine treatment showed no side effects on salivary glands function.
本研究的目的是使用高锝酸盐-99m（(99m)Tc-P）唾液腺闪烁扫描术评估左西替利嗪（开思亭）对过敏性鼻炎患者唾液腺功能的影响。研究人群包括67例过敏性鼻炎患者和31名健康对照者（14名男性和17名女性，平均年龄30.1±6.8岁）。患者被分为两组：未治疗患者组，共32例患者，17名男性和15名女性，平均年龄29.9±6.5岁；左西替利嗪治疗组，给予5mg·天⁻¹治疗4周，共35例患者，16名男性和19名女性，平均年龄33.5±7.8岁。所有患者和健康对照者均接受唾液腺闪烁扫描术。静脉注射185MBq的(99m)Tc-P后，进行25分钟的动态唾液腺闪烁扫描。通过时间-活性曲线，计算腮腺和颌下唾液腺的以下腺功能参数：摄取率、最大蓄积量和排出分数。我们的结果显示：未治疗患者组获得的所有功能参数均显著低于左西替利嗪治疗患者组和健康对照者（P<0.05）。左西替利嗪治疗患者组与健康对照者之间的任何功能参数均无显著差异（P>0.05）。总之，我们的研究结果表明，与未治疗患者和健康对照者相比，接受左西替利嗪治疗的过敏性鼻炎患者唾液腺功能显著更高。左西替利嗪治疗对唾液腺功能无副作用。
